Non-cancerous complications in HTLV-1 carriers

References

• Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. doi: 10.3389/fmicb.2012.00388
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322. doi: 10.3389/fmicb.2012.00322
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801. J Clin Oncol. 2007;25(34):5458–5464. doi: 10.1200/JCO.2007.11.9958
   PubMed Web of Science ®Google Scholar
• Bangham CR, Araujo A, Yamano Y, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers. 2015;1(1):15012.
   PubMedGoogle Scholar
• De Castro-Costa CM, Araújo AQ, Barreto MM, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses. 2006;22(10):931–935. doi: 10.1089/aid.2006.22.931
   PubMed Web of Science ®Google Scholar
• Talukder MR, Woodman R, Pham H, et al. High human T cell leukemia virus type 1c proviral loads are associated with diabetes and chronic kidney disease: results of a cross-sectional community survey in central Australia. Clin Infect Dis. 2023;76(3):e820–e826. doi: 10.1093/cid/ciac614
   PubMed Web of Science ®Google Scholar
• Yamanashi H, Koyamatsu J, Nagayoshi M, et al. Human T-cell leukemia virus-1 infection is associated with atherosclerosis as measured by carotid intima-media thickness in Japanese community-dwelling older people. Clin Infect Dis. 2018;67(2):291–294. doi: 10.1093/cid/ciy168
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Fuji S, Kohmo S, et al. HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. Expert Rev Anti Infect Ther. 2023;21(1):57–63. doi: 10.1080/14787210.2023.2151437
   PubMed Web of Science ®Google Scholar
• Schierhout G, McGregor S, Gessain A, et al. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133–143. doi: 10.1016/S1473-3099(19)30402-5
   PubMed Web of Science ®Google Scholar
• Liu Z, Chu A. Sjögren’s syndrome and viral infections. Rheumatol Ther. 2021;8(3):1051–1059. doi: 10.1007/s40744-021-00334-8
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee JS, Shin MG, et al. Detection of HTLV-1 in the labial salivary glands of patients with Sjögren’s syndrome: a distinct clinical subgroup? J Rheumatol. 2012;39(4):809–815. doi: 10.3899/jrheum.111075
   PubMed Web of Science ®Google Scholar
• Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren’s syndrome. The Lancet. 1994;344(8930):1116–1119. doi: 10.1016/S0140-6736(94)90630-0
   PubMed Web of Science ®Google Scholar
• Nakamura H, Takagi Y, Kawakami A, et al. HTLV-I infection results in resistance toward salivary gland destruction of Sjögren’s syndrome. Clin Exp Rheumatol. 2008;26:653–5. 4
   PubMed Web of Science ®Google Scholar
• Nakamura H, Shimizu T, Takagi Y, et al. Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome. BMC Musculoskelet Disord. 2015;16(1):335. doi: 10.1186/s12891-015-0773-1
   PubMedGoogle Scholar
• Nakamura H, Tsukamoto M, Nagasawa Y, et al. Does HTLV-1 infection show phenotypes found in Sjögren’s syndrome? Viruses. 2022;14(1):100. doi: 10.3390/v14010100
   PubMed Web of Science ®Google Scholar
• Hida A, Imaizumi M, French B, et al. Association of human T-cell leukemia virus type 1 with prevalent rheumatoid arthritis among atomic bomb survivors: a cross-sectional study. Medicine (Baltimore). 2021;100(24):e26297. doi: 10.1097/MD.0000000000026297
   PubMed Web of Science ®Google Scholar
• Quaresma JA, Yoshikawa GT, Koyama RV, et al. HTLV-1, immune response and autoimmunity. Viruses. 2015;8(1):5. doi: 10.3390/v8010005
   PubMed Web of Science ®Google Scholar
• Terada Y, Kamoi K, Ohno-Matsui K, et al. Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: a case report. Medicine (Baltimore). 2017;96(6):e6021. doi: 10.1097/MD.0000000000006021
   PubMed Web of Science ®Google Scholar
• Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020;172(5):ITC33–ITC48. doi: 10.7326/AITC202003030
   PubMed Web of Science ®Google Scholar
• Cruz BA, Catalan-Soares B, Proietti F. Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol. 2006;33:2300–2303.
   PubMed Web of Science ®Google Scholar
• Dugardin J, Demar M, Hafsi N, et al. Human T-cell leukemia virus type 1 is associated with dysthyroidism in the French Amazon. Front Cell Infect Microbiol. 2023;13:1164526. doi: 10.3389/fcimb.2023.1164526
   PubMed Web of Science ®Google Scholar
• Akamine H, Takasu N, Komiya I, et al. Association of HTLV-I with autoimmune thyroiditis in patients with adult T-cell leukaemia (ATL) and in HTLV-I carriers. Clin Endocrinol (Oxf). 1996;45(4):461–466. doi: 10.1046/j.1365-2265.1996.741562.x
   PubMed Web of Science ®Google Scholar
• Kawai H, Saito M, Takagi M, et al. Hashimoto’s thyroiditis in HTLV-I carriers. Intern Med. 1992;31(10):1213–1216. doi: 10.2169/internalmedicine.31.1213
   PubMed Web of Science ®Google Scholar
• Al-Saleem J, Dirksen WP, Martinez MP, et al. HTLV-1 tax-1 interacts with SNX27 to regulate cellular localization of the HTLV-1 receptor molecule, GLUT1. PloS One. 2019;14(3):e0214059. doi: 10.1371/journal.pone.0214059
   PubMed Web of Science ®Google Scholar
• Talukder MR, Clauss CS, Cherian S, et al. Risk factors for HTLV-1, acute kidney injury, and urinary tract infection among aboriginal adults with end stage kidney disease in central Australia. J Med Virol. 2021;93(11):6362–6370. doi: 10.1002/jmv.27163
   PubMed Web of Science ®Google Scholar
• Smikle MF, Wright-Pascoe R, Barton EN, et al. Autoantibodies, human T lymphotropic virus type 1 and type 1 diabetes mellitus in Jamaicans. West Indian Med J. 2002;51:153–156.
   PubMed Web of Science ®Google Scholar
• Layegh P, Shoeibi A, Nikkhah K, et al. Can HTLV-1 infection be a potential risk factor for atherosclerosis? Intervirology. 2014;57(6):365–368. doi: 10.1159/000365785
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Arima K, Noguchi Y, et al. Possible mechanisms underlying the association between human T-cell leukemia virus type 1 (HTLV-1) and hypertension in elderly Japanese population. Environ Health Prev Med. 2021;26(1):17. doi: 10.1186/s12199-021-00938-0
   PubMed Web of Science ®Google Scholar
• Kamrani M, Saryazdi S, Zemorshidi F, et al. Cognitive deficits in HTLV-1 patients. J Neurovirol. 2023;29(4):416–424. doi: 10.1007/s13365-023-01139-x
   PubMed Web of Science ®Google Scholar
• Kalil RS, Vasconcellos I, Rosadas C, et al. Association between high proviral load, cognitive impairment, and white matter brain lesions in HTLV-1-infected individuals. J Neurovirol. 2021;27(6):810–819. doi: 10.1007/s13365-021-00944-6
   PubMed Web of Science ®Google Scholar
• de Paula JJ, Romanelli LC, de Faria RCV, et al. Cognitive impairment in the HTLV-1 infection: a comparative study associated with functional performance. J Neurovirol. 2021;27(6):849–856. doi: 10.1007/s13365-020-00905-5
   PubMed Web of Science ®Google Scholar
• Champs APS, de Azeredo Passos VM, Carvalho G, et al. Cognitive impairment in HTLV-1-associated myelopathy, proviral load and inflammatory markers. Int J Infect Dis. 2019;84:121–126. doi: 10.1016/j.ijid.2019.05.010
   PubMed Web of Science ®Google Scholar
• de Oliveira CJV, Neto JAC, Andrade RCP, et al. Risk factors for erectile dysfunction in men with HTLV-1. J Sex Med. 2017;14(10):1195–1200. doi: 10.1016/j.jsxm.2017.08.001
   PubMed Web of Science ®Google Scholar
• Oliveira P, Castro NM, Muniz AL, et al. Prevalence of erectile dysfunction in HTLV-1–infected patients and its association with overactive bladder. Urology. 2010;75(5):1100–1103. doi: 10.1016/j.urology.2009.11.041
   PubMed Web of Science ®Google Scholar
• Carneiro Neto JA, Vitor de Oliveira CJ, Ferraz SN, et al. Bladder dysfunction in human T cell lymphotropic virus infection: a prospective cohort study. PloS Negl Trop Dis. 2022;16(1):e0009772. doi: 10.1371/journal.pntd.0009772
   PubMed Web of Science ®Google Scholar
• de Oliveira CJV, Neto JAC, Liberato de Matos SNF, et al. Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study. J Sex Med. 2023;20(3):269–276. doi: 10.1093/jsxmed/qdac050
   PubMed Web of Science ®Google Scholar
• Grassi MF, Dos Santos NP, Lírio M, et al. Tuberculosis incidence in a cohort of individuals infected with human T-lymphotropic virus type 1 (HTLV-1) in Salvador, Brazil. BMC Infect Dis. 2016;16(1):491. doi: 10.1186/s12879-016-1428-z
   PubMedGoogle Scholar
• Souza A, Carvalho N, Neves Y, et al. Association of tuberculosis status with neurologic disease and immune response in HTLV-1 infection. AIDS Res Hum Retroviruses. 2017;33(11):1126–1133. doi: 10.1089/aid.2015.0340
   PubMed Web of Science ®Google Scholar
• Kawano N, Nagahiro Y, Yoshida S, et al. Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016. J Clin Exp Hematop. 2019;59(4):156–167. doi: 10.3960/jslrt.18032
   PubMed Web of Science ®Google Scholar
• Kameda T, Utsunomiya A, Otsuka N, et al. Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers. BMC Infect Dis. 2024;24(1):96. doi: 10.1186/s12879-024-09001-z
   PubMed Web of Science ®Google Scholar
• McGill NK, Vyas J, Shimauchi T, et al. HTLV-1-associated infective dermatitis: updates on the pathogenesis. Exp Dermatol. 2012;21(11):815–821. doi: 10.1111/exd.12007
   PubMed Web of Science ®Google Scholar
• La Grenade L, Manns A, Fletcher V, et al. Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I–associated infective dermatitis in children. Arch dermatol. 1998;134(4):439–444. doi: 10.1001/archderm.134.4.439
   PubMedGoogle Scholar
• Lee R, Schwartz RA. Human T-lymphotrophic virus type 1–associated infective dermatitis: a comprehensive review. J Am Acad Dermatol. 2011;64(1):152–160. doi: 10.1016/j.jaad.2009.10.021
   PubMed Web of Science ®Google Scholar
• Farre L, de Oliveira Mde F, Primo J, et al. Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma. Clin Infect Dis. 2008;46(3):440–442. doi: 10.1086/524695
   PubMed Web of Science ®Google Scholar
• de Oliveira Mde F, Fatal PL, Primo JR, et al. Infective dermatitis associated with human T-cell lymphotropic virus type 1: evaluation of 42 cases observed in Bahia, Brazil. Clin Infect Dis. 2012;54:1714–1719. doi: 10.1093/cid/cis273
   PubMed Web of Science ®Google Scholar
• Souza LS, Silva TS, de Oliveira MFP, et al. Clinicopathological aspects and proviral load of adulthood infective dermatitis associated with HTLV-1: comparison between juvenile and adulthood forms. PloS Negl Trop Dis. 2020;14(4):e0008241. doi: 10.1371/journal.pntd.0008241
   PubMed Web of Science ®Google Scholar
• Kamoi K, Watanabe T, Uchimaru K, et al. Updates on HTLV-1 uveitis. Viruses. 2022;14(4):794. doi: 10.3390/v14040794
   PubMed Web of Science ®Google Scholar
• Ikeda E, Ono A, Hikita N, et al. Estimated prevalence rate of HTLV-I uveitis in Chikugo. J Jpn Ophthalmol Soc. 1998;102:327–332.
   Google Scholar
• Kamoi K. HTLV-1 in ophthalmology. Front Microbiol. 2020;11:388. doi: 10.3389/fmicb.2020.00388
   PubMed Web of Science ®Google Scholar
• Kamoi K. Current challenges facing the clinical treatment for HTLV-1 ocular manifestations. Expert Rev Ophthalmol. 2023;18(6):405–419. doi: 10.1080/17469899.2023.2281446
   Web of Science ®Google Scholar
• Kamoi K, Horiguchi N, Kurozumi-Karube H, et al. Horizontal transmission of HTLV-1 causing uveitis. Lancet Infect Dis. 2021;21(4):578. doi: 10.1016/S1473-3099(21)00063-3
   PubMed Web of Science ®Google Scholar
• Kamoi K, Mochizuki M. HTLV infection and the eye. Curr Opin Ophthalmol. 2012;23(6):557–561. doi: 10.1097/ICU.0b013e328358b9ec
   PubMed Web of Science ®Google Scholar
• Kamoi K, Okayama A, Izumo S, et al. Adult T-cell leukemia/lymphoma-related ocular manifestations: analysis of the first large-scale nationwide survey. Front Microbiol. 2019;9:3240. doi: 10.3389/fmicb.2018.03240
   PubMed Web of Science ®Google Scholar
• Miyanaga M, Shimizu K, Kawaguchi T, et al. A clinical survey of uveitis in HTLV-1 endemic region. Ocul Immunol Inflamm. 2009;17(5):335–341. doi: 10.3109/09273940903137667
   PubMed Web of Science ®Google Scholar
• Nakao K, Abematsu N, Sakamoto T. Systemic diseases in patients with HTLV-1-associated uveitis. Br J Ophthalmol. 2018;102(3):373–376. doi: 10.1136/bjophthalmol-2017-310658
   PubMed Web of Science ®Google Scholar
• Kamoi K, Mochizuki M. HTLV-1 uveitis. Front Microbiol. 2012;3:270. doi: 10.3389/fmicb.2012.00270
   PubMed Web of Science ®Google Scholar
• Kase S, Namba K, Kitaichi N, et al. Clinical features of human T lymphotropic virus type 1-associated uveitis in Hokkaido, Japan. Jpn J Ophthalmol. 2013;57(4):379–384. doi: 10.1007/s10384-013-0244-x
   PubMed Web of Science ®Google Scholar
• Piai Ozores D, Rathsam Pinheiro R, Boa-Sorte N, et al. Prevalence and characteristics of HTLV-associated uveitis in patients from Bahia, an endemic area for HTLV − 1 in Brazil. Virol J. 2023;20(1):185. doi: 10.1186/s12985-023-02135-7
   PubMed Web of Science ®Google Scholar
• Araujo A, Bangham CRM, Casseb J, et al. Management of HAM/TSP: systematic review and consensus-based recommendations 2019. Neurol Clin Pract. 2021;11(1):49–56. doi: 10.1212/CPJ.0000000000000832
   PubMedGoogle Scholar
• Sato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (anti-CCR4) in HTLV-1–associated Myelopathy. N Engl J Med. 2018;378(6):529–538. doi: 10.1056/NEJMoa1704827.
   PubMed Web of Science ®Google Scholar
• Sato T, Nagai M, Watanabe O, et al. Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy. J Neurol. 2024. doi: 10.1007/s00415-024-12239-x
   PubMedGoogle Scholar
• Meyerowitz EA, Mukerji SS, Kyle Harrold G, et al. Mogamulizumab for treatment of human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis: a single-center US-based series. Clin Infect Dis. 2023;77(6):851–856. doi: 10.1093/cid/ciad281
   PubMed Web of Science ®Google Scholar
• Olindo S, Belrose G, Gillet N, et al. Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood. 2011;118(24):6306–6309. doi: 10.1182/blood-2011-04-349910
   PubMed Web of Science ®Google Scholar
• Martin F, Castro H, Gabriel C, et al. Ciclosporin a proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis. PloS Negl Trop Dis. 2012;6(6):e1675. doi: 10.1371/journal.pntd.0001675
   PubMed Web of Science ®Google Scholar
• Enose-Akahata Y, Billioux BJ, Azodi S, et al. Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP. Ann Clin Transl Neurol. 2021;8(10):1970–1985. doi: 10.1002/acn3.51437
   PubMed Web of Science ®Google Scholar
• Koseki A, Araya N, Yamagishi M, et al. EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy. Front Microbiol. 2023;14:1175762. doi: 10.3389/fmicb.2023.1175762
   PubMed Web of Science ®Google Scholar
• Pasquier A, Alais S, Roux L, et al. How to control HTLV-1-associated diseases: preventing de novo cellular infection using antiviral therapy. Front Microbiol. 2018;9:278. doi: 10.3389/fmicb.2018.00278
   PubMed Web of Science ®Google Scholar
• Kchour G, Makhoul NJ, Mahmoudi M, et al. Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma. 2007;48(2):330–336. doi: 10.1080/10428190601071717
   PubMed Web of Science ®Google Scholar
• Cook LB, Rowan AG, Demontis MA, et al. Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma. Int J Hematol. 2018;107(3):378–382. doi: 10.1007/s12185-017-2361-7
   PubMed Web of Science ®Google Scholar
• Saito M. Association between HTLV-1 genotypes and risk of HAM/TSP. Front Microbiol. 2019;10:1101. doi: 10.3389/fmicb.2019.01101
   PubMed Web of Science ®Google Scholar